Literature DB >> 16110787

Specific molecular features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus.

J P Latgé1, I Mouyna, F Tekaia, A Beauvais, J P Debeaupuis, W Nierman.   

Abstract

The cell wall of Aspergillus fumigatus is composed of a branched beta1,3 glucan covalently bound to chitin, beta1,3, beta1,4 glucans, and galactomannan, that is embedded in an amorphous cement composed of alpha1,3 glucan, galactomannan and polygalactosamin. The mycelial cell wall of A. fumigatus is very different from the yeast Saccharomyces cerevisiae cell wall, and in particular lacks beta1,6 glucans and proteins covalently bound to cell wall polysaccharides. The differences in cell wall composition between the mould A. fumigatus and the yeast S. cerevisiae are also reflected at the genomic level where unique features have been identified in A. fumigatus. A single gene codes for the glucan synthase catalytic subumit; this finding has lead to the development of a RNAi methodology for the disruption of essential genes in A. fumigatus. In contrast to the glucan synthase, multiple genes have been found in the chitin synthase and the alpha glucan synthase families; in spite of homologous sequences, each gene in each family have very different function. Similarly homologous mannosyltransferase genes are found in yeast and moulds but they lead to the synthesis of very different N-mannan structures. This chemo-genomic comparative analysis has also suggested that GPI-anchored proteins do not have a role of linker in the three dimensional organization of the fungal cell wall.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110787     DOI: 10.1080/13693780400029155

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  46 in total

Review 1.  Aspergillus fumigatus: principles of pathogenesis and host defense.

Authors:  Tobias M Hohl; Marta Feldmesser
Journal:  Eukaryot Cell       Date:  2007-09-21

2.  Optimisation of a 2-D gel electrophoresis protocol for the human-pathogenic fungus Aspergillus fumigatus.

Authors:  Olaf Kniemeyer; Franziska Lessing; Olaf Scheibner; Christian Hertweck; Axel A Brakhage
Journal:  Curr Genet       Date:  2005-12-17       Impact factor: 3.886

Review 3.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

Review 4.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

Review 5.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

6.  Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus.

Authors:  John G Gibbons; Anne Beauvais; Remi Beau; Kriston L McGary; Jean-Paul Latgé; Antonis Rokas
Journal:  Eukaryot Cell       Date:  2011-07-01

7.  Neurospora crassa 1,3-α-glucan synthase, AGS-1, is required for cell wall biosynthesis during macroconidia development.

Authors:  Ci Fu; Asuma Tanaka; Stephen J Free
Journal:  Microbiology (Reading)       Date:  2014-05-20       Impact factor: 2.777

8.  Co-ordination between BrlA regulation and secretion of the oxidoreductase FmqD directs selective accumulation of fumiquinazoline C to conidial tissues in Aspergillus fumigatus.

Authors:  Fang Yun Lim; Brian Ames; Christopher T Walsh; Nancy P Keller
Journal:  Cell Microbiol       Date:  2014-04-15       Impact factor: 3.715

9.  A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis.

Authors:  Aki Yoneda; Tamara L Doering
Journal:  Mol Biol Cell       Date:  2006-10-04       Impact factor: 4.138

10.  Role of ficolin-A and lectin complement pathway in the innate defense against pathogenic Aspergillus species.

Authors:  Stefan Bidula; Hany Kenawy; Youssif M Ali; Darren Sexton; Wilhelm J Schwaeble; Silke Schelenz
Journal:  Infect Immun       Date:  2013-03-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.